In the last session, Creative Medical Technology Holdings (OTC – CELZ) opened its trading at 0.0238 and closed at $0.0278, an increase of 44.79%. There were 415,117,372 shares traded in the last session compared with 98,568,509 shares during the previous 30 days. Moreover, the most recent 52-week price range for the stock was from $0.0013 to$0.105.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
So, what was behind this rush…
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On the last day of the troublesome year 2020, In a preclinical study, Creative Medical Technology Holdings Inc. recently reported positive results using ImmCelz to treat a model of a heart attack.
Read More
Ex Vivo reprogrammed immune cells are used as a treatment for heart failure and post-infarct pathological remodeling of mice with restricted blood flow, which will significantly improve survival compared to controls.
Amit Patel, CEO of the company and co-inventor of a patent on the immune system, said that it is “no exaggeration” that the immune system is involved in numerous different aspects of regenerative medicine. “Today’s preliminary results support the notion that a “regenerative immunotherapy” referred to as ImmCelz could be used across a broad spectrum of conditions.”
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Drs Thomas Ichim and Amit Patel have spent decades of work developing the ImmCelz product. It involves the extraction of patient immune cells, incubation with regenerative cells outside of the body, and reinfusion of the patient’s cells. Its results to date have demonstrated the effectiveness of ImmCelz for the treatment of strokes and liver failure.